Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Oncology

Treatment and Survivorship: Navigating the Long Term

At a Glance

Familial melanoma is primarily treated with surgery, while advanced cases often respond exceptionally well to immunotherapy. Because genetic mutations increase the risk for multiple new cancers, lifelong screening is essential for early detection and improving long-term survival.

When it comes to treatment, the medical community treats familial melanoma with the same high standards and advanced tools used for sporadic melanoma. However, because your biology is unique, there are specific factors your care team will consider regarding your response to treatment and your long-term outlook.

Standard Treatment: Surgery First

The primary treatment for melanoma, whether familial or sporadic, is surgical excision [1][2].

  • Early Detection: Because patients with familial melanoma are often under close surveillance, tumors are frequently caught at a very early stage (Stage 0 or 1), where surgery is often the only treatment needed [3][4].
  • Multiple Primaries: It is important to know that people with mutations like CDKN2A are at a higher risk for developing Multiple Primary Melanomas (MPM)—new, separate cancers rather than the original one spreading [5]. This means you may face multiple surgeries over your lifetime, each aimed at removing a new site of concern [6].

Advanced Treatment: The Immunotherapy Advantage

If melanoma reaches an advanced stage (Stage III or IV), doctors use systemic treatments like immunotherapy, which helps your immune system recognize and attack cancer cells.

  • Response Rates: There is encouraging evidence that patients with CDKN2A mutations may respond exceptionally well to immune checkpoint inhibitors (such as anti-PD-1 and anti-CTLA-4 therapies) [7].
  • Tumor Mutational Burden (TMB): Some research suggests that these mutations may lead to a higher “mutational load” in the tumor [7]. Simply put, the more mutations a tumor has, the more “unusual” it looks to your immune system, making it an easier target for immunotherapy drugs [7][8].

Prognosis and Outlook

Your prognosis—the likely course and outcome of the disease—is influenced by several factors:

  • Survival Rates: Interestingly, some studies show that patients with familial melanoma may have better relapse-free survival than those with sporadic melanoma [9]. This is largely attributed to the fact that these patients are monitored so closely that their cancers are caught earlier [3].
  • Mutation Impact: While early detection is a major advantage, having a CDKN2A mutation itself can be associated with more aggressive disease if it is not caught early [10][11]. This highlights why staying on top of your screening schedule is the single most important thing you can do for your health [12].

The Psychological Side of Survivorship

Being a “previvor” (someone with a high genetic risk) or a survivor of familial melanoma comes with a unique psychological weight.

  • “Scanxiety”: The cycle of chronic monitoring—the constant skin checks and internal scans—can lead to “melanoma-specific distress” [13]. It is common to feel anxious in the days leading up to an appointment.
  • Family Concerns & Communication: Many patients feel a sense of “genetic guilt” regarding their children or siblings [13]. Talking to your extended family about genetic results can be daunting. It helps to provide them with clear, factual information—perhaps even a letter written with your genetic counselor—explaining what the mutation is, how it affects their risk, and how they can get tested or start screening themselves.
  • Multidisciplinary Support: Because your risk may involve multiple organs (like the pancreas or eyes), your survivorship is best managed by a team—including dermatologists, oncologists, and even neurologists—who talk to each other to coordinate your care [14][15]. Speaking with a psycho-oncologist can also help you process feelings and shift the focus from fear to empowerment through prevention [16][17].

Common questions in this guide

Will I need multiple surgeries if I have familial melanoma?
Because genetic mutations increase your risk of developing multiple primary melanomas, you may need several surgical excisions over your lifetime. Each surgery is designed to safely remove a new, distinct tumor before it has the chance to spread.
How do genetic mutations impact my response to immunotherapy?
Patients with certain mutations, like CDKN2A, often respond exceptionally well to immune checkpoint inhibitors. These genetic changes can create a higher tumor mutational burden, making the cancer cells an easier target for your immune system to recognize and attack.
What is scanxiety and how is it managed?
Scanxiety is the psychological distress and chronic worry patients feel before regular skin checks or internal imaging scans. Managing this anxiety is a normal part of survivorship and can be supported by working with a psycho-oncologist or specialized care team.
Is familial melanoma more aggressive than sporadic melanoma?
Certain mutations can lead to more aggressive tumors if they are not detected quickly. However, because familial patients undergo strict, lifelong surveillance, their cancers are frequently caught much earlier, which can actually lead to better relapse-free survival rates.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.If I need systemic treatment, how does my CDKN2A or BAP1 status affect my likely response to immunotherapy like Nivolumab or Pembrolizumab?
  2. 2.Should my surgical margins be wider or different because of my genetic risk for multiple primary melanomas?
  3. 3.Can you help me understand the 'Tumor Mutational Burden' (TMB) of my cancer and if it relates to my family mutation?
  4. 4.How do we distinguish between a recurrence of my original melanoma and a completely new primary tumor?
  5. 5.Do you recommend a specific survivorship clinic or psychologist familiar with the stress of lifelong monitoring?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Surgical Management of Melanoma: Advances and Updates.

    Santamaria-Barria JA, Mammen JMV

    Current oncology reports 2022; (24(11)):1425-1432 doi:10.1007/s11912-022-01289-x.

    PMID: 35657482
  2. 2

    European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.

    Garbe C, Amaral T, Peris K, et al.

    European journal of cancer (Oxford, England : 1990) 2020; (126()):159-177 doi:10.1016/j.ejca.2019.11.015.

    PMID: 31866016
  3. 3

    Surveillance, CDKN2A and survival of familial melanoma.

    van Doorn R

    Journal of the European Academy of Dermatology and Venereology : JEADV 2023; (37(2)):218-219 doi:10.1111/jdv.18796.

    PMID: 36640377
  4. 4

    CDKN2A Mutation: A Patient's and Physician's Experience.

    Shaked Y, Swearingen A, Liebman TN

    Dermatology and therapy 2025; (15(2)):265-268 doi:10.1007/s13555-025-01354-w.

    PMID: 39921829
  5. 5

    Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.

    Helgadottir H, Tuominen R, Olsson H, et al.

    Journal of the American Academy of Dermatology 2017; (77(5)):893-901 doi:10.1016/j.jaad.2017.05.050.

    PMID: 28818438
  6. 6

    Analysis of the CDKN2A Gene in FAMMM Syndrome Families Reveals Early Age of Onset for Additional Syndromic Cancers.

    Middlebrooks CD, Stacey ML, Li Q, et al.

    Cancer research 2019; (79(11)):2992-3000 doi:10.1158/0008-5472.CAN-18-1580.

    PMID: 30967399
  7. 7

    Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations.

    Helgadottir H, Ghiorzo P, van Doorn R, et al.

    Journal of medical genetics 2020; (57(5)):316-321 doi:10.1136/jmedgenet-2018-105610.

    PMID: 30291219
  8. 8

    Tumor-Infiltrating Immune-Related Long Non-Coding RNAs Indicate Prognoses and Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma.

    Ma B, Jiang H, Luo Y, et al.

    Frontiers in immunology 2021; (12()):692079 doi:10.3389/fimmu.2021.692079.

    PMID: 34737735
  9. 9

    Solar Lentigines are Associated with Better Outcome in Cutaneous Melanoma.

    Marasigan V, Güvenç C, Oord JJ, et al.

    Acta dermato-venereologica 2019; (99(12)):1154-1159 doi:10.2340/00015555-3270.

    PMID: 31314121
  10. 10

    Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.

    Helgadottir H, Höiom V, Tuominen R, et al.

    Journal of the National Cancer Institute 2016; (108(11)) doi:10.1093/jnci/djw135.

    PMID: 27287845
  11. 11

    Melanoma-specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non-carriers.

    Pissa M, Lapins J, Sköldmark C, Helgadottir H

    Journal of the European Academy of Dermatology and Venereology : JEADV 2023; (37(2)):284-292 doi:10.1111/jdv.18589.

    PMID: 36156317
  12. 12

    CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition.

    Chan SH, Chiang J, Ngeow J

    Hereditary cancer in clinical practice 2021; (19(1)):21 doi:10.1186/s13053-021-00178-x.

    PMID: 33766116
  13. 13

    A Systematic Review on the Impact of Genetic Testing for Familial Melanoma II: Psychosocial Outcomes and Attitudes.

    Primiero CA, Yanes T, Finnane A, et al.

    Dermatology (Basel, Switzerland) 2021; (237(5)):816-826 doi:10.1159/000513576.

    PMID: 33508831
  14. 14

    Recurrent melanoma development in a Caucasian female with CDKN2A+ mutation and FAMMM syndrome: A case report.

    Gu K, Velde RV, Pitz M, Silver S

    SAGE open medical case reports 2020; (8()):2050313X20936034 doi:10.1177/2050313X20936034.

    PMID: 32953120
  15. 15

    Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report.

    Jeong AR, Forbes K, Orosco RK, Cohen EEW

    Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale 2022; (51(1)):5 doi:10.1186/s40463-022-00556-y.

    PMID: 35123577
  16. 16

    Genetic testing for familial melanoma.

    Primiero CA, Maas EJ, Wallingford CK, et al.

    Italian journal of dermatology and venereology 2024; (159(1)):34-42 doi:10.23736/S2784-8671.23.07761-7.

    PMID: 38287743
  17. 17

    Outcomes of endoscopic ultrasound as a one-off pancreatic cancer screening tool for 122 high- and moderate-risk patients.

    Efthymiou M, Chandran S, Zorron Cheng Tao Pu L, et al.

    JGH open : an open access journal of gastroenterology and hepatology 2020; (4(6)):1217-1223 doi:10.1002/jgh3.12432.

    PMID: 33319059

This page provides educational information about familial melanoma treatment and survivorship. Always consult your oncology team for medical advice tailored to your specific genetic mutation and diagnosis.

Get notified when new evidence is published on Familial melanoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.